Narrow search
Showing 1 - 10 of 20,470
Cover Image
Pharmaceutical regulation in Europe and its impact on corporate R&D
Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9
expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically … assessing the impact of regulation on pharmaceutical R&D expenditures. Methods: We analyze a sample of 20 leading pharmaceutical … companies between 2000 and 2008. The share of sales in Europe serves as a proxy for the degree of pharmaceutical regulation. We …
Persistent link: https://www.econbiz.de/10010526909
Cover Image
Find and replace : R&D investment following the erosion of existing products
Krieger, Joshua; Li, Xuelin - 2018
Persistent link: https://www.econbiz.de/10012019907
Cover Image
R&D and financial systems: the determinants of R&Dexpenditures in the Swedish pharmaceutical industry
Malmberg, Claes - Centre for Innovation, Research and Competence in the … - 2008
This study investigates the determinants of R&D expenditures in the Swedish pharmaceutical industry from the 1960s to the mid 1990s. Various proxies for the rate of return of R&D (e.g. expected profit, sales and R&D productivity) as well as the availability of internal funding (proxied by past...
Persistent link: https://www.econbiz.de/10008764489
Cover Image
Drug problem or medicrime? : distribution and use of falsified Tramadol medication in Egypt and West Africa
Klein, Axel - In: Journal of illicit economies and development : JIED 1 (2019) 1, pp. 52-62
patient well-being. A further shift is needed away from repressive measures against consumers, to tighter regulation in the …
Persistent link: https://www.econbiz.de/10012260588
Cover Image
Pharmaceutical regulation at the wholesale level and parallel trade
Birg, Laura - 2013
This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by …
Persistent link: https://www.econbiz.de/10010223101
Cover Image
Regulation of pharmaceutical prices : evidence from a reference price reform in Denmark ; conference paper
Kaiser, Ulrich; Méndez, Susan; Rønde, Thomas; … - 2013 - This version: February 23, 2013
Reference prices constitute a main determinant of patient health care reimbursement in many countries. We study the effects of a change from an "external" (based on a basket of prices in other countries) to an "internal" (based on comparable domestic products) reference price system. We find...
Persistent link: https://www.econbiz.de/10010339324
Cover Image
How do drug prices respond to a change from external to internal reference pricing? : evidence from a Danish regulatory reform
Kaiser, Ulrich; Méndez, Susan J. - 2015
We study the effects of a change in the way patient reimbursements are calculated on the prices of pharmaceuticals using quasi-experimental data for Denmark which switched from external (where reimbursements are based on prices of similar products in foreign countries) to internal reference...
Persistent link: https://www.econbiz.de/10010467805
Cover Image
How do drug prices respond to a change from external to internal reference pricing? : evidence from a Danish regulatory reform
Kaiser, Ulrich; Méndez, Susan J. - 2015
Persistent link: https://www.econbiz.de/10010503427
Cover Image
How do drug prices respond to a change from external to internal reference pricing? : evidence from a Danish regulatory reform
Kaiser, Ulrich; Mendez, Susan J. - 2015 - This version: January 5, 2015
We study the effects of a change in the way patient reimbursements are calculated on the prices of pharmaceuticals using quasi-experimental data for Denmark which switched from external (where reimbursements are based on prices of similar products in foreign countries) to internal reference...
Persistent link: https://www.econbiz.de/10010462523